At close: September 27 at 4:00 PM EDT
After hours: September 27 at 7:38 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.44 | -0.4 | -3.44 | -1.53 |
| Low Estimate | -0.55 | -0.48 | -4.47 | -2.4 |
| High Estimate | -0.27 | -0.29 | -2.54 | -0.93 |
| Year Ago EPS | -2.8 | -2.5 | -10.2 | -3.44 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | 390k | 400k | 1.82M | 1.98M |
| Low Estimate | 300k | 320k | 1.64M | 1.4M |
| High Estimate | 490k | 520k | 2.02M | 3.03M |
| Year Ago Sales | 150k | 63k | 709k | 1.82M |
| Sales Growth (year/est) | 160.00% | 534.90% | 156.70% | 8.80% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -2.25 | -2.1 | -2 | -0.87 |
| EPS Actual | -2.8 | -2.5 | -1.61 | -1.83 |
| Difference | -0.55 | -0.4 | 0.39 | -0.96 |
| Surprise % | -24.40% | -19.00% | 19.50% | -110.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.44 | -0.4 | -3.44 | -1.53 |
| 7 Days Ago | -0.44 | -0.4 | -3.44 | -1.53 |
| 30 Days Ago | -0.44 | -0.4 | -3.44 | -1.53 |
| 60 Days Ago | -0.64 | -0.52 | -3.22 | -2.04 |
| 90 Days Ago | -0.88 | -0.68 | -3.86 | -2.67 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | LGVN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 84.30% | -- | -- | 5.60% |
| Next Qtr. | 84.00% | -- | -- | 9.90% |
| Current Year | 66.30% | -- | -- | 3.40% |
| Next Year | 55.50% | -- | -- | 12.70% |
| Next 5 Years (per annum) | -- | -- | -- | 11.90% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/4/2024 |
| Maintains | Maxim Group: Buy to Buy | 8/27/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/15/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 7/31/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 7/29/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/17/2024 |
Related Tickers
VRAX Virax Biolabs Group Limited
1.9400
+0.52%
ADTX Aditxt, Inc.
0.1633
-25.60%
SNGX Soligenix, Inc.
3.7600
-2.34%
ENSC Ensysce Biosciences, Inc.
0.2880
+4.73%
WINT Windtree Therapeutics, Inc.
2.5700
-5.17%
ANVS Annovis Bio, Inc.
8.10
-1.70%
CING Cingulate Inc.
5.03
-2.14%
XCUR Exicure, Inc.
3.6400
-4.46%
GOVX GeoVax Labs, Inc.
2.4500
-0.81%
CERO CERo Therapeutics Holdings, Inc.
0.0920
-2.44%